HBM Holdings (HKSE:02142) Short-Term Debt : HK$432.1 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is HBM Holdings Short-Term Debt?

HBM Holdings's Short-Term Debt for the quarter that ended in Dec. 2024 was HK$432.1 Mil.

HBM Holdings's quarterly Short-Term Debt increased from Dec. 2023 (HK$285.5 Mil) to Jun. 2024 (HK$340.0 Mil) and increased from Jun. 2024 (HK$340.0 Mil) to Dec. 2024 (HK$432.1 Mil).

HBM Holdings's annual Short-Term Debt declined from Dec. 2022 (HK$320.0 Mil) to Dec. 2023 (HK$285.5 Mil) but then increased from Dec. 2023 (HK$285.5 Mil) to Dec. 2024 (HK$432.1 Mil).

HBM Holdings Short-Term Debt Historical Data

The historical data trend for HBM Holdings's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HBM Holdings Short-Term Debt Chart

HBM Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Short-Term Debt

Get a 7-Day Free Trial

6.22

320.03

285.53

432.08

HBM Holdings Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Short-Term Debt	Get a 7-Day Free Trial								320.03	308.10	285.53	339.97	432.08

HBM Holdings Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

HBM Holdings Short-Term Debt Related Terms

Thank you for viewing the detailed overview of HBM Holdings's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

HBM Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HBM Holdings Ltd (HKSE:02142) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

HBMHF:USA 6XY:Germany

Address

218 Xinghu Street, Suite 202, Building A3, Suzhou Industrial Park, Suzhou, CHN, 215123

Website

https://www.harbourbiomed.com

HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the United States.

Executives

Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Wang Jingsong	2101 Beneficial owner
Advantech Capital L.p.
Pang Kee Chan Hebert
Golden Link Investment Limited
Advantech Capital Partners Ltd.
Advantech Master Investment Limited
Astrazeneca Plc	2201 Interest of corporation controlled by you
Gic Private Limited	2102 Investment manager
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd.	2201 Interest of corporation controlled by you
Gic Special Investments Private Limited	2102 Investment manager
Owap Investment Pte Ltd	2101 Beneficial owner
Advantech Capital Holdings Ltd.
Jun Lian Zi Ben Guan Li Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you

HBM Holdings Headlines

No Headlines